Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats

dc.contributor.authorTaşkın, Mine İslimye
dc.contributor.authorYay, Arzu
dc.contributor.authorAdalı, Ertan
dc.contributor.authorBalcıoğlu, Esra
dc.contributor.authorİnceboz, Ümit
dc.date.accessioned2019-10-17T10:35:30Z
dc.date.available2019-10-17T10:35:30Z
dc.date.issued2015en_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionTaşkın, Mine İslimye (Balikesir Author)en_US
dc.description.abstractThe aim of this study is to evaluate the effects of sildenafil citrate on cisplatin-induced ovarian toxicity. Thirty-two female rats were divided into four groups. Group 1: saline control; group 2: cisplatin; group 3: sildenafil citrate; and group 4: cisplatin plus sildenafil citrate group. In groups 2 and 4, the rats were injected with 5 mg/kg cisplatin intraperitoneally (i.p.). In groups 3 and 4, the rats were injected with 1.4 mg/kg sildenafil citrate i.p. The ovaries were removed two weeks later in all groups. Histopathologic examination, follicle counting and classification were performed. The expression of anti-Mullerian hormone (AMH) was detected immunohistochemically in the ovarian tissues. Sildenafil alleviated cisplatin-induced histopathological changes in the ovarian tissue. Primordial, secondary and tertiary follicles were diminished in group 2 compared with group 1 (p <0.05). Pretreatment with sildenafil citrate preserved primordial follicle count in group 4 compared with group 2, and the difference was statistically significant (p <0.05). According to our results, immunoreactivity intensity of AMH was lower in group 2 compared with group 1 (92.4 +/- 3.97 versus 88.8 +/- 1.77) but not significantly, whereas immunoreactivity intensity of AMH was higher in group 4 compared with group 2 (88.8 +/- 1.77 versus 94.1 +/- 2.36; p<0.05). Our results demonstrated that pretreatment with sildenafil citrate is beneficial for protecting the ovaries from cisplatin-induced damage. Sildenafil citrate can be a choice for fertility preservation.en_US
dc.identifier.doi10.3109/09513590.2014.984679
dc.identifier.endpage277en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84931031056
dc.identifier.scopusqualityQ2
dc.identifier.startpage272en_US
dc.identifier.urihttps://doi.org/10.3109/09513590.2014.984679
dc.identifier.urihttps://hdl.handle.net/20.500.12462/8161
dc.identifier.volume31en_US
dc.identifier.wosWOS:000358466600006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectAMHen_US
dc.subjectCisplatinen_US
dc.subjectPrimordial Follicleen_US
dc.subjectSildenafil Citrateen_US
dc.titleProtective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in ratsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
mine-islimye-taskın5.pdf
Boyut:
1.5 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: